Elsevier

The Lancet

Volume 305, Issue 7915, 10 May 1975, Page 1083
The Lancet

Letters to the Editor
CLOFIBRATE AND GALLSTONES

https://doi.org/10.1016/S0140-6736(75)91845-0Get rights and content

References (3)

  • D. Pertsemlidis et al.

    Gastroenterology

    (1974)
There are more references available in the full text version of this article.

Cited by (49)

  • Triglycerides and gallstone formation

    2010, Clinica Chimica Acta
    Citation Excerpt :

    The fact that bezafibrate improves gallbladder motility in HTG patients is of potential clinical relevance. Earlier studies showed an increased incidence of gallstones under fibrate therapy [57,72,73]. However, in those studies the majority of treated patients were hypercholesterolemic and not hypertriglyceridemic.

  • An interpretive history of the cholesterol controversy, part IV: The 1984 Coronary Primary Prevention Trial ends it - Almost

    2006, Journal of Lipid Research
    Citation Excerpt :

    Clofibrate was quite effective, decreasing blood cholesterol by ∼20%, and it had already been reported to significantly reduce cardiac end points in high-risk men (14). However, it was more effective in decreasing VLDL than LDL, and its use had been associated with significant increases in gallstones (15) and other diseases of the gastrointestinal tract. Later studies would show that the drug, although having a favorable effect on cardiac events, actually increased overall mortality (16).

View all citing articles on Scopus
View full text